Glucose Metabolism Gene Expression Patterns and Tumor Uptake of 18F- Fluorodeoxyglucose After Radiation Treatment George D. Wilson, PhD, Bryan J. Thibodeau,

Slides:

Advertisements

Similar presentations

A Quantitative Analysis of the Relationship Between Radiation Therapy Use and Travel Time Emma Liu, MM, Pablo Santibáñez, MM, Martin L. Puterman, PhD,

Advertisements

125I reimplantation in patients with poor initial dosimetry after prostate brachytherapy Mira Keyes, MD, Tom Pickles, MD, Alexander Agranovich, MD, Winkle.

Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate.

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review David.

COSMIC: A Regimen of Intensity Modulated Radiation Therapy Plus Dose-Escalated, Raster-Scanned Carbon Ion Boost for Malignant Salivary Gland Tumors: Results.

Correlation of 18F-FDG Avid Volumes on Pre–Radiation Therapy and Post–Radiation Therapy FDG PET Scans in Recurrent Lung Cancer Nadya Shusharina, PhD,

The Case for Prostate Brachytherapy in the Affordable Care Act Era

Benjamin D. Rosenbluth, M. D. , Victoria Serrano, B. S

Toxicity of Gamma Knife Radiosurgery in the Treatment of Intracranial Tumors in Patients With Collagen Vascular Diseases or Multiple Sclerosis Dot Lowell,

Dose and Spatial Effects in Long-Distance Radiation Signaling In Vivo: Implications for Abscopal Tumorigenesis Mariateresa Mancuso, PhD, Paola Giardullo,

The Role of Diffusion-Weighted Magnetic Resonance Imaging in the Treatment Response Evaluation of Hepatocellular Carcinoma Patients Treated With Radiation.

Decline of Tumor Vascular Function as Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging Is Associated With Poor Responses to Radiation.

Validation of Heat Shock Protein 70 as a Tumor-Specific Biomarker for Monitoring the Outcome of Radiation Therapy in Tumor Mouse Models Christine Bayer,

Pre-operative hyperfractionated radiotherapy and concurrent 5-fu/cisplatin for locally advanced esophageal cancer - the impact of 18-F-fluoro-deoxy-d-glucose.

Xiaoyan Wu, M. D. , Ph. D. , Peili Chen, M. D. , Ph. D. , Stephen T

Radiotherapy treatment planning and long-term follow-up with [11C]methionine PET in patients with low-grade astrocytoma Joanne Nuutinen, M.D., Pirkko.

Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From.

A Dose Escalation and Pharmacodynamic Study of Triapine and Radiation in Patients With Locally Advanced Pancreas Cancer Ludmila Katherine Martin, MD,

18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy

Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma—Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group

Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports Daniel K. Ebner, BS, Tadashi Kamada, MD, PhD,

T. Liu, J. Zhou, S. A. Woodhouse, P. B. Schiff, P. Zhang, K. S

Lactate-Base 1H Magnetic Spectroscopy Does Not Predict Response and Outcomes in Patients With Stage IV Head and Neck Squamous Cell Carcinoma Q. Le, A.

Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With.

Individualized Positron Emission Tomography–Based Isotoxic Accelerated Radiation Therapy Is Cost-Effective Compared With Conventional Radiation Therapy:

Close or Positive Margins After Mastectomy for DCIS: Pattern of Relapse and Potential Indications for Radiotherapy Afshin Rashtian, M.D., Shawn Iganej,

Morten Hoyer, Ph. D. , Henrik Roed, D. M. Sc

A New Model for Imaging and Radiation Therapy Quality Assurance in the National Clinical Trials Network of the National Cancer Institute Thomas J. FitzGerald,

Obituary and Tribute to John “Jack” Francis Fowler, PhD, DSc ( )

Continuing Risk of Ipsilateral Breast Relapse After Breast-Conserving Therapy at Long- Term Follow-up Bas Kreike, M.D., Augustinus A.M. Hart, M.Sc., Tony.

Frederiek M. Lever, MD, Irene M. Lips, MD, PhD, Sjoerd P. M

Simultaneous positron emission tomography (PET) assessment of metabolism with 18F- fluoro-2-deoxy-d-glucose (FDG), proliferation with 18F-fluoro-thymidine.

Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast.

Dose–Volume Relationships Associated With Temporal Lobe Radiation Necrosis After Skull Base Proton Beam Therapy Mark W. McDonald, MD, Okechukwu R. Linton,

Lifetime Increased Cancer Risk in Mice Following Exposure to Clinical Proton Beam– Generated Neutrons Leo E. Gerweck, PhD, Peigen Huang, MD, Hsiao-Ming.

Adjuvant Therapy in High-Risk Stage III Cutaneous Melanoma

Vaginal Motion and Bladder and Rectal Volumes During Pelvic Intensity-Modulated Radiation Therapy After Hysterectomy Anuja Jhingran, M.D., Mohammad Salehpour,

Active Breathing Control in Combination With Ultrasound Imaging: A Feasibility Study of Image Guidance in Stereotactic Body Radiation Therapy of Liver.

Radiation Therapy and Hearing Loss

Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab′)2 Jörgen Elgqvist,

FDG PET-CT Aids in the Preoperative Assessment of Patients with Newly Diagnosed Thymic Epithelial Malignancies Marcelo F.K. Benveniste, MD, Cesar A.

Complete Metabolic Response Is Not Uniformly Predictive of Complete Pathologic Response After Induction Therapy for Esophageal Cancer Brendon M. Stiles,

A High Content Clonogenic Survival Drug Screen Identifies MEK Inhibitors as Potent Radiation Sensitizers for KRAS Mutant Non–Small-Cell Lung Cancer Steven.

Diffusion-weighted magnetic resonance imaging in preoperative assessment of non– small cell lung cancer Hiroaki Nomori, MD, Yue Cong, MD, Masaru Abe,

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Interpretation Criteria for Assessment of Antibiotic Treatment Response in Pyogenic.

Sclerosing Pneumocytoma with Lymph Node Metastasis

Clinical and Translational Radiation Oncology

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

Unexpected Small Bowel Intussusception Caused by Lung Cancer Metastasis on 18F- Fluorodeoxyglucose PET-CT Jeong Won Lee, MD, Seok-Ki Kim, MD, Ji Won Park,

Glucose Metabolism in NSCLC Is Histology-Specific and Diverges the Prognostic Potential of 18FDG-PET for Adenocarcinoma and Squamous Cell Carcinoma Olga.

A Severe Photosensitivity Dermatitis Caused by Crizotinib

Preliminary Report of Late Recurrences, at 5 Years or More, after Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer Yukinori Matsuo,

A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Sung Hee Lim, MD, Ji-Yun Lee, MD, Jong-Mu Sun, MD, PhD, Kyoung-Mee Kim,

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Interpretation Criteria for Assessment of Antibiotic Treatment Response in Pyogenic.

A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance

Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by 18FDG-PET/CT Rosario Mazzola, MD, Alba Fiorentino,

Arnaud Uguen, MD, PhD Journal of Thoracic Oncology

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

A Case of Nontuberculous Mycobacteria Highly Suspected as Lung Cancer Invading the Aortic Arch Tadashi Umehara, MD, Masaya Aoki, MD, PhD, Aya Harada,

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Axillary Mass and Hypercalcemia: The Value of a Physical Examination

Histological Subtypes of Lung Adenocarcinoma Have Differential 18F- Fluorodeoxyglucose Uptakes on the Positron Emission Tomography/Computed Tomography.

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

Marianna Koczywas, MD, Mihaela C. Cristea, MD

Metastatic Lung Cancer to the Pancreas

Role of Positron Emission Tomography/Computed Tomography Findings for Adjuvant Chemotherapy Indications in Stage T1b-2aN0M0 Lung Adenocarcinoma Shinsuke.

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Super Scan Using Positron Emission Tomography in Lung Cancer Patients

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Presentation transcript:

Glucose Metabolism Gene Expression Patterns and Tumor Uptake of 18F- Fluorodeoxyglucose After Radiation Treatment George D. Wilson, PhD, Bryan J. Thibodeau, PhD, Laura E. Fortier, MS, Barbara L. Pruetz, BS, Sandra Galoforo, MS, Andrew M. Baschnagel, MD, John Chunta, PhD, Ching Yee Oliver Wong, MD, Di Yan, PhD, Brian Marples, PhD, Jiayi Huang, MD International Journal of Radiation Oncology • Biology • Physics Volume 90, Issue 3, Pages 620-627 (November 2014) DOI: 10.1016/j.ijrobp.2014.06.062 Copyright © 2014 Elsevier Inc. Terms and Conditions

Fig. 1 Tumor growth and changes in positron emission tomography (PET) parameters in response to irradiation. (A) Growth curves for control (solid line) and tumors irradiated with 15 Gy (dotted lines). (B) Typical 18F-fluorodeoxyglucose-PET images of a control tumor xenograft (upper) at day 10 and an irradiated tumor (lower) at day 12. The tumors display the contouring used to assess core and periphery PET signals. (C) Changes in kinetic index (Ki) as a function of time after treatment in controls (solid lines) and irradiated tumors (dotted line). (D-F) Same a C except for retention index, sensitivity factor, and maximum standardized uptake value (SUVmax), respectively. All data are mean ± SEM. International Journal of Radiation Oncology • Biology • Physics 2014 90, 620-627DOI: (10.1016/j.ijrobp.2014.06.062) Copyright © 2014 Elsevier Inc. Terms and Conditions

Fig. 2 Changes in GLUT1 (A) protein levels after radiation treatment. The solid lines represent control tumors, whereas the dotted lines are tumors irradiated with 15 Gy. The lower panel shows representative immunohistochemical staining of tumors for a control (B), day 12 after irradiation (C), and day 21 after irradiation (D). International Journal of Radiation Oncology • Biology • Physics 2014 90, 620-627DOI: (10.1016/j.ijrobp.2014.06.062) Copyright © 2014 Elsevier Inc. Terms and Conditions

Fig. 3 Changes in HK2 (A) protein levels after radiation treatment. The solid lines represent control tumors, whereas the dotted lines are tumors irradiated with 15 Gy. The lower panel shows representative immunohistochemical staining of tumors for a control (B), day 7 after irradiation (C), and day 21 after irradiation (D). International Journal of Radiation Oncology • Biology • Physics 2014 90, 620-627DOI: (10.1016/j.ijrobp.2014.06.062) Copyright © 2014 Elsevier Inc. Terms and Conditions

Fig. 4 Correlation between changes in kinetic index (Ki) and GLUTI (A) and HK2 (B) protein levels after irradiation. The open symbols represent the mean values for each time point after irradiation (Δ) or sham irradiation (O), whereas the closed symbols represent the individual data points for irradiated (▲) and nonirradiated (●) tumors. International Journal of Radiation Oncology • Biology • Physics 2014 90, 620-627DOI: (10.1016/j.ijrobp.2014.06.062) Copyright © 2014 Elsevier Inc. Terms and Conditions